Pure Global AI
NCT06277245Recruiting

A Phase 3 Study of LNK01001 Capsule in Subjects With Moderate to Severe Atopic Dermatitis.

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate LNK01001 in Adults Subjects With Moderate to Severe Atopic Dermatitis.
Lynk Pharmaceuticals Co., LtdPhase 3ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Atopic Dermatitis
Drug/Device/Intervention
LNK01001
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Lynk Pharmaceuticals Co., Ltd
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 3
Start date
Feb 06, 2024
End date
Nov 30, 2025
Enrollment
354 participants
Primary outcome

Eczema Area and Severity Index (EASI-75) at Week 16,Investigator's Global Assessment (IGA) score of 0/1 at Week 16

Summary

This is a randomized, double-blind study comparing LNK01001 to placebo in participants with
 moderately to severely atopic dermatitis who were candidates for systemic therapy (ie,
 patients with a history of inadequate response to topical treatments, those who were using a
 systemic treatment, or those for whom topical treatments are otherwise medically
 inadvisable).
 
 The objective of this study is to evaluate the efficacy and safety of LNK01001 in adult
 patients with moderate to severe AD who are candidates for systemic therapy.

ICD-10 classifications
Atopic dermatitisAtopic dermatitis, unspecifiedOther atopic dermatitisAcute atopic conjunctivitisAllergic contact dermatitis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06277245
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06277245 through Pure Global AI's free database. This Phase 3 trial is sponsored by Lynk Pharmaceuticals Co., Ltd and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 354 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.